Genetic Engineering and Biotechnology News (GEN)
These sources consist of legitimate science or are evidence based through the use of credible scientific sourcing. Legitimate science follows the scientific method, is unbiased and does not use emotional words. These sources also respect the consensus of experts in the given scientific field and strive to publish peer reviewed science. Some sources in this category may have a slight political bias, but adhere to scientific principles. See all Pro-Science sources.
- Overall, we rate GEN a Pro-Science source based on use of peer reviewed science as sources for news reporting.
Factual Reporting: HIGH
World Press Freedom Rank: USA 48/180
Founded in 1980 by Mary Ann Liebert, Genetic Engineering and Biotechnology News is a publication reporting on the fields of gene editing, drug discovery and industry news. According to their about page “GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities.”
Read our profile on United States government and media.
Funded by / Ownership
GEN is owned and published by Mary Ann Liebert, Inc. and revenue is derived from advertising and subscription fees.
Analysis / Bias
In review, GEN publishes news that is sourced from peer reviewed publications such as this: Cancer-Killing T Cells Subdued, Kept “Stemmy,” by Potassium. Gen also covers industry news such as this: Lilly, ImmuNext Launch Up-to-$605M+ Autoimmune Disease Collaboration. In general, there is little bias and all information is soucred properly.
Overall, we rate GEN a Pro-Science source based on use of peer reviewed science as sources for news reporting. (D. Van Zandt 3/30/2019)
Protecting you from fake news sites since 2015